Medico Remedies (BOM:540937) 5-Year EBITDA Growth Rate : 23.60% (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Medico Remedies 5-Year EBITDA Growth Rate?

Medico Remedies's EBITDA per Share for the three months ended in Dec. 2023 was ₹0.35.

During the past 12 months, Medico Remedies's average EBITDA Per Share Growth Rate was -5.40% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was 41.70% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 23.60% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 18.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 11 years, the highest 3-Year average EBITDA Per Share Growth Rate of Medico Remedies was 41.70% per year. The lowest was 3.70% per year. And the median was 17.50% per year.

Competitive Comparison of Medico Remedies's 5-Year EBITDA Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Medico Remedies's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Medico Remedies's 5-Year EBITDA Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Medico Remedies's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Medico Remedies's 5-Year EBITDA Growth Rate falls into.

Medico Remedies 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Medico Remedies (BOM:540937) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Medico Remedies 5-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Medico Remedies's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Medico Remedies (BOM:540937) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Medico Remedies Ltd (BOM:540937) » Definitions » 5-Year EBITDA Growth Rate

Traded in Other Exchanges

MEDICO:India

Address

N. S. Phadke Marg, Opposite Teligali, 1105/1106, 11th Floor, Hubtown Solaris, Andheri (East), Mumbai, MH, IND, 400069

Website

https://www.medicoremedies.com

Medico Remedies Ltd is a manufacturer, supplier, and exporter of pharmaceutical drugs. It focuses on the production and marketing of anti-infective, cephalosporins, antimalarial, antiretroviral, anti-ulcer drugs and antacids, vitamins, haematinics, and other supplements. In addition, it also sells other drugs such as antihistaminic, antidiabetics, cardiovascular drugs, diuretics, anti-epileptics, combination drug kits, syrups and cream, and gel for various therapeutic segments.

Medico Remedies (BOM:540937) Headlines

No Headlines